By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s ...

Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines ...

Pfizer Inc. (NYSE:PFE) is one of the 8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA lowered the price target on ...

Pfizer has a significant dividend payout, yielding over 6%. With its forward price-to-earnings (P/E) ratio of 9.6, it may ...

Now, it’s worth noting Stock Advisor’s total average return is 959 % — a market-crushing outperformance compared to 191% for ...

Doctors break down what you need to know about the four-dose vaccine.

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

The news is the latest example of the biotech industry's struggles in the Bay Area.

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...